Drug interactions
Lorlatinib + Upadacitinib
Severity: Moderate
Lorlatinib and Upadacitinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib induces CYP3A4 and may lower upadacitinib exposure, possibly reducing disease control. Strong CYP3A4 inducers reduce upadacitinib exposure, and lorlatinib is a weaker inducer.
What this interaction means in plain words
Lorlatinib and Upadacitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Lorlatinib belongs to Oncology; Upadacitinib belongs to Musculoskeletal.
Why it happens
CYP3A4 induction by lorlatinib increases upadacitinib metabolism.
What to do
Monitor for reduced efficacy of upadacitinib. Consider an alternative if disease control is lost.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lorlatinib and Upadacitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Other interactions of Upadacitinib
- Abrocitinib + Upadacitinib Contraindicated
- Adenovirus types 4 and 7 live + Upadacitinib Contraindicated
- Baricitinib + Upadacitinib Contraindicated
- Bcg vaccine live + Upadacitinib Contraindicated
- Dengue vaccine + Upadacitinib Contraindicated
- Influenza virus vaccine quadrivalent intranasal + Upadacitinib Contraindicated
Frequently asked questions
Can I take Lorlatinib with Upadacitinib?
MediHelp rates the interaction as moderate. Lorlatinib and Upadacitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lorlatinib induces CYP3A4 and may lower upadacitinib exposure, possibly reducing disease control. Strong CYP3A4 inducers reduce upadacitinib exposure, and lorlatinib is a weaker inducer.
How serious is the interaction between Lorlatinib and Upadacitinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for reduced efficacy of upadacitinib. Consider an alternative if disease control is lost.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
